Based on previous smaller studies, it looked like an approach called intermittent androgen deprivation therapy might be just as good as continuous androgen deprivation in terms of survival while meanwhile giving patients a breather from the side effects of therapy. But this new study, which treated 1,535 patients with metastatic prostate cancer and followed them for a median of 10 years, finds that's not the case. Read more here.
Study mentioned: Hussain M, et al. Intermittent versus Continuous Androgen Deprivation in Prostate Cancer. N Engl J Med 2013; 368:1314-1325.
No comments:
Post a Comment